Research programme: infectious diseases vaccines - Bacilligen

Drug Profile

Research programme: infectious diseases vaccines - Bacilligen

Alternative Names: BVS-based AIDS vaccine - Bacilligen; BVS-based HIV vaccine - Bacilligen; BVS-based influenza vaccine - Bacilligen

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bacilligen
  • Class AIDS vaccines; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections; Influenza virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in USA (Parenteral)
  • 15 May 2009 Early research in HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top